Answers are grounded in this paper and cite their sources.
Community acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide. Its impact is greatest in the elderly, and in immunocompromised individuals and those with comorbidities.1 CAP causes pulmonary and systemic inflammation that can impair gas exchange. There has been ongoing interest in the anti-inflammatory role of glucocorticoids in the treatment of CAP over the past 50 years,2 yet the role of adjuvant corticosteroid therapy remains controversial. Large randomised controlled trials (RCTs) including CAPE-COD3 and SONIA4 found reduced mortality with corticosteroids in severe CAP, findings supported by a meta-analysis of 30 RCTs.
No takes yet. Share an insight, caveat, or question.
Teja et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: